Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Umbilical cord mesenchymal stem cell conditioned media (RISTEK-BRIN)
- Development stage
- Unknown
- Lead developer
- National Research and Innovation Agency
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intraarticular
01
Overview
Umbilical cord mesenchymal stem cell conditioned media (UC-MSC-CM) is a biologic therapy derived from the secretome of mesenchymal stem cells harvested from the human umbilical cord and cultured under hypoxic conditions. This conditioned media contains a concentrated mixture of paracrine factors, including cytokines, chemokines, growth factors, and extracellular vesicles such as exosomes. These components work synergistically to provide immunomodulatory, anti-inflammatory, and regenerative effects within the joint environment. Developed by the Indonesian Ministry of Research and Technology / National Research and Innovation Agency (RISTEK-BRIN), the therapy is administered via intra-articular injection to treat knee osteoarthritis by reducing synovial inflammation and promoting the repair of articular cartilage and subchondral bone.
- Other names
- Hypoxic umbilical cord mesenchymal stem cell conditioned mediaUC-MSC secretomeUC-MSC-CMIntra-articular secretome injection therapy
Beyond the preview
Go deeper on Umbilical cord mesenchymal stem cell conditioned media (RISTEK-BRIN).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Umbilical cord mesenchymal stem cell conditioned media (RISTEK-BRIN).